Drugs.com
DECEMBER 16, 2023
SATURDAY, Dec. 16 -- It's that time of year when your kids come home with sniffles and sore throats, but when should you worry if they have a fever?To a certain extent, fevers are the body's natural way of fighting infection, one expert.
Elrig
DECEMBER 16, 2023
Hope Amos, Scientific Communication Specialist at Nanolive SA, unveils Nanolive's groundbreaking label-free, machine learning-powered assays, revolutionizing drug discovery. Discover how their holotomography technology offers high-resolution, 3D imaging of cellular components, shedding light on metabolic stress without cell death. The post Machine learning powered assays advance drug discovery first appeared on ELRIG.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Codon
DECEMBER 16, 2023
This newsletter began as a side project. In the summer of 2020, I was living in a closet-sized apartment (and paying $2,650 each month for the privilege) in New York City’s Lower East Side. I spent my cramped weekends scouring the Internet for research papers and pasting them into this newsletter. Eventually, I began to write longer essays, too, and the newsletter slowly grew in size.
Elrig
DECEMBER 16, 2023
Join Stuart Farrow, VP of Biosciences at Cancer Research Horizons, as he reveals groundbreaking insights with SelectScience on AI, immuno-oncology, and personalized medicine's synergy in advancing effective cancer treatments. The post Why personalized medicine is the future of cancer treatment first appeared on ELRIG.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
DECEMBER 16, 2023
VENTOLIN HFA (albuterol sulfate) Glaxosmithkline Patent: 7,832,351 Expiration: Dec 19, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of December 17, 2023 appeared first on DrugPatentWatch - Make Better Decisions.
Common Sense for Drug Policy Blog
DECEMBER 16, 2023
Entheogens "An entheogen is a psychoactive compound, typically from natural sources such as plants or fungi, that can be used to alter consciousness for spiritual purposes ( Johnstad, 2018 ). Thousands of years of knowledge from traditional medicine practices outlined the dose, efficacy, and preparation of many natural medicines and have demonstrated that entheogens are a powerful tool for healing various conditions ( Yuan, Ma, Ye, & Piao, 2016 ).
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Common Sense for Drug Policy Blog
DECEMBER 16, 2023
Treatment for Methamphetamine Use "Methamphetamine is a highly addictive psychostimulant with evidence of neurotoxic properties ( 1 – 3 ) and is consistently ranked as one of the most harmful illicit substances—both to the person using and to society ( 4 , 5 ). Methamphetamine use disorder is a chronic relapsing condition increasingly associated with harms that include mental and physical illness, intimate partner violence, family disruption, health care system pressures, homelessness, crime, an
Drug Patent Watch
DECEMBER 16, 2023
Dasatinib is the generic ingredient in two branded drugs marketed by Apotex and Bristol Myers Squibb and is included in three NDAs. There are two patents protecting this compound. Drug… The post New tentative approval for Teva Pharms drug dasatinib appeared first on DrugPatentWatch - Make Better Decisions.
Codon
DECEMBER 16, 2023
This newsletter began as a side project. In the summer of 2020, I was living in a closet-sized apartment (and paying $2,650 each month for the privilege) in New York City’s Lower East Side. I spent my cramped weekends scouring the Internet for research papers and pasting them into this newsletter. Eventually, I began to write longer essays, too, and the newsletter slowly grew in size.
Common Sense for Drug Policy Blog
DECEMBER 16, 2023
Psilocybin Therapy "Psilocybin is a non-addictive classic psychedelic ( 22 , 23 ) with neuroplasticity-inducing properties ( 24 , 25 ). It is consistently ranked as one of the least harmful illicit psychoactive substances ( 4 , 5 ), despite being among the most highly regulated substances globally. Psilocybin is a tryptamine alkaloid with serotonin 2A receptor (5-HT2 A ) agonism ( 26 )—and complex pharmacology at many additional serotonin and non-serotonin receptors—that induces marked transitor
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
DECEMBER 16, 2023
This chart shows the pharmaceutical companies with the most patents in Netherlands. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Netherlands? appeared first on DrugPatentWatch - Make Better Decisions.
Common Sense for Drug Policy Blog
DECEMBER 16, 2023
Use and Efficacy of Ketamine for Alcohol Use Disorder "The potential use of ketamine for AUD was first suggested in 1972 ( 32 , 33 ). Possible hypotheses for ketamine use in AUD include balancing cortical glutamate homeostasis and enhancing neuroplasticity which may facilitate learning and acquiring new skills, especially those that help individuals cope with drinking ( 29 , 34 ).
New Drug Approvals
DECEMBER 16, 2023
Iptacopan 1644670-37-0 422.525, C 25 H 30 N 2 O 4 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl) benzoic acid BENZOIC ACID, 4-((2S,4S)-4-ETHOXY-1-((5-METHOXY-7-METHYL-1H-INDOL-4-YL)METHYL)-2-PIPERIDINYL)- Iptacopan LNP 023 LNP-023 LNP023 NVP-LNP023 NVP-LNP023-NX fda approved, To treat paroxysmal nocturnal hemoglobinuria, 12/5/2023, Fabhalta ‘ Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood
Common Sense for Drug Policy Blog
DECEMBER 16, 2023
Ketamine Treatment for Alcohol Use Disorder "There is increasing interest in the use of ketamine as an adjunct to treatment of AUD and management of AWS. There were three studies that showed the benefit of using ketamine as an adjunctive treatment to conventional first-line therapies in patients with severe AWS. Ketamine was added to the medication regimen when AWS was refractory to BZD or after clinical signs of delirium tremens (DT).
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Expert insights. Personalized for you.
105 
Let's personalize your content